BR112017023486A2 - processo para preparar um composto, e, composto - Google Patents
processo para preparar um composto, e, compostoInfo
- Publication number
- BR112017023486A2 BR112017023486A2 BR112017023486A BR112017023486A BR112017023486A2 BR 112017023486 A2 BR112017023486 A2 BR 112017023486A2 BR 112017023486 A BR112017023486 A BR 112017023486A BR 112017023486 A BR112017023486 A BR 112017023486A BR 112017023486 A2 BR112017023486 A2 BR 112017023486A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- polymorph
- salts
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
Abstract
a presente invenção fornece novos processos para preparar compostos de fórmula (iv) e sais dos mesmos, novos intermediários, e um novo sal e polimorfo do mesmo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1509492.3 | 2015-06-02 | ||
| GBGB1509492.3A GB201509492D0 (en) | 2015-06-02 | 2015-06-02 | Novel processes |
| PCT/EP2016/062250 WO2016193255A1 (en) | 2015-06-02 | 2016-05-31 | Processes to make indazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017023486A2 true BR112017023486A2 (pt) | 2018-07-24 |
| BR112017023486B1 BR112017023486B1 (pt) | 2023-02-14 |
Family
ID=53677608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017023486-6A BR112017023486B1 (pt) | 2015-06-02 | 2016-05-31 | Processo para preparar derivados de indazol |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10266525B2 (pt) |
| EP (1) | EP3303329B1 (pt) |
| JP (1) | JP6389967B2 (pt) |
| KR (1) | KR20180011115A (pt) |
| CN (1) | CN107660204B (pt) |
| AU (1) | AU2016273752B2 (pt) |
| BR (1) | BR112017023486B1 (pt) |
| CA (1) | CA2983966A1 (pt) |
| CY (1) | CY1122343T1 (pt) |
| DK (1) | DK3303329T3 (pt) |
| ES (1) | ES2760571T3 (pt) |
| GB (1) | GB201509492D0 (pt) |
| HR (1) | HRP20192117T1 (pt) |
| HU (1) | HUE047523T2 (pt) |
| ME (1) | ME03653B (pt) |
| PL (1) | PL3303329T3 (pt) |
| PT (1) | PT3303329T (pt) |
| RS (1) | RS59639B1 (pt) |
| RU (1) | RU2017134467A (pt) |
| SI (1) | SI3303329T1 (pt) |
| WO (1) | WO2016193255A1 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2759476C (en) * | 2009-04-30 | 2018-10-09 | Julie Nicole Hamblin | Novel compounds |
| ES2602972T3 (es) * | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
| PL2614058T3 (pl) | 2010-09-08 | 2015-12-31 | Glaxosmithkline Ip Dev Ltd | Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu |
| GB201018124D0 (en) * | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| CA2925064A1 (en) * | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
-
2015
- 2015-06-02 GB GBGB1509492.3A patent/GB201509492D0/en not_active Ceased
-
2016
- 2016-05-31 ME MEP-2019-326A patent/ME03653B/me unknown
- 2016-05-31 BR BR112017023486-6A patent/BR112017023486B1/pt active IP Right Grant
- 2016-05-31 ES ES16726309T patent/ES2760571T3/es active Active
- 2016-05-31 PL PL16726309T patent/PL3303329T3/pl unknown
- 2016-05-31 RU RU2017134467A patent/RU2017134467A/ru not_active Application Discontinuation
- 2016-05-31 CN CN201680029002.0A patent/CN107660204B/zh active Active
- 2016-05-31 JP JP2017562313A patent/JP6389967B2/ja active Active
- 2016-05-31 PT PT167263094T patent/PT3303329T/pt unknown
- 2016-05-31 WO PCT/EP2016/062250 patent/WO2016193255A1/en active Application Filing
- 2016-05-31 US US15/578,258 patent/US10266525B2/en active Active
- 2016-05-31 DK DK16726309T patent/DK3303329T3/da active
- 2016-05-31 EP EP16726309.4A patent/EP3303329B1/en active Active
- 2016-05-31 CA CA2983966A patent/CA2983966A1/en not_active Abandoned
- 2016-05-31 KR KR1020177033696A patent/KR20180011115A/ko unknown
- 2016-05-31 AU AU2016273752A patent/AU2016273752B2/en not_active Ceased
- 2016-05-31 RS RS20191554A patent/RS59639B1/sr unknown
- 2016-05-31 HU HUE16726309A patent/HUE047523T2/hu unknown
- 2016-05-31 SI SI201630555T patent/SI3303329T1/sl unknown
-
2019
- 2019-11-26 HR HRP20192117TT patent/HRP20192117T1/hr unknown
- 2019-12-04 CY CY20191101273T patent/CY1122343T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6389967B2 (ja) | 2018-09-12 |
| RU2017134467A3 (pt) | 2019-10-11 |
| US20180155334A1 (en) | 2018-06-07 |
| ES2760571T3 (es) | 2020-05-14 |
| PL3303329T3 (pl) | 2020-03-31 |
| CN107660204B (zh) | 2021-04-13 |
| PT3303329T (pt) | 2019-12-16 |
| CN107660204A (zh) | 2018-02-02 |
| AU2016273752A1 (en) | 2017-10-19 |
| JP2018518477A (ja) | 2018-07-12 |
| WO2016193255A1 (en) | 2016-12-08 |
| GB201509492D0 (en) | 2015-07-15 |
| RU2017134467A (ru) | 2019-07-15 |
| RS59639B1 (sr) | 2020-01-31 |
| EP3303329B1 (en) | 2019-09-18 |
| HUE047523T2 (hu) | 2020-04-28 |
| EP3303329A1 (en) | 2018-04-11 |
| CY1122343T1 (el) | 2021-01-27 |
| CA2983966A1 (en) | 2016-12-08 |
| BR112017023486B1 (pt) | 2023-02-14 |
| SI3303329T1 (sl) | 2020-02-28 |
| HRP20192117T1 (hr) | 2020-02-21 |
| US10266525B2 (en) | 2019-04-23 |
| AU2016273752B2 (en) | 2018-07-05 |
| KR20180011115A (ko) | 2018-01-31 |
| DK3303329T3 (da) | 2019-12-02 |
| ME03653B (me) | 2020-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
| ECSP18010535A (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CO2017012403A2 (es) | Proceso para preparar 4-amino-piridazinas | |
| BR112017006253A2 (pt) | novos compostos | |
| BR112017006240A2 (pt) | novos compostos | |
| AR087451A1 (es) | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes | |
| CO2017000337A2 (es) | Derivados de bis(aril)catecol como herbicidas | |
| BR112017006116A2 (pt) | processos de preparação de compostos e compostos | |
| BR112017009471A2 (pt) | síntese de copanlisib e seu sal de di-hidrocloreto. | |
| BR112017009876A2 (pt) | processos e intermediários para a preparação de éteres de dialcano terminados em ácido alfa,ômega-dicarboxílico | |
| EA201590788A1 (ru) | Аминные соли лахинимода | |
| BR112016023391A8 (pt) | processos, compostos, composições farmacêutica, benzenossulfonatos, ácidos, formas a e b de ácido ptoluenssulfônico, formas i e ii do ácido naftalendissulfônico. | |
| BR112017002268A2 (pt) | sal de derivado de piridina monocíclica e cristal do mesmo | |
| CY1120763T1 (el) | Νεες ενωσεις σουλφονυλαμινοβενζαμιδιου | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| CL2018001067A1 (es) | Compuesto piranodipiridínico. | |
| MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
| NZ702935A (en) | Process for making hydroxylated cyclopentylpyrimidine compounds | |
| BR112017019850A2 (pt) | ?processo melhorado para a preparação de apremilast? | |
| BR112016029510A2 (pt) | métodos para a preparação de um composto, e, composto intermediário. | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| BR112014018712A8 (pt) | Derivados de morfolinila úteis como inibidores de mogat-2 | |
| EA201990238A1 (ru) | ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC | |
| BR112014018738A8 (pt) | Métodos e intermediários para preparo de agentes farmacêuticos | |
| EA202090933A1 (ru) | Способ получения гербицидных соединений пиридазинона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/05/2016, OBSERVADAS AS CONDICOES LEGAIS |
|
| B25G | Requested change of headquarter approved |
Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) |